Science
Unpredicted binding found between SARS-CoV-2 and hepatitis C drug, telaprevir – Drug Target Review
Insights into the interaction between telaprevir and the SARS-CoV-2 main protease could aid in future COVID-19 drug design, say scientists.
Posted: 24 March 2021 | Victoria Rees (Drug Target Review) | No comments yet
Insights into the interaction between telaprevir and the SARS-CoV-2 main protease could aid in future COVID-19 drug design, say scientists.
Scientists have found new, unexpected behaviours when SARS-CoV-2 – the virus that causes COVID-19 – encounters drug inhibitors, which bind to certain components of the virus and block its ability to reproduce.
According to the team, from the US Department of Energy’s Oak Ridge National…
-
General23 hours agoKim Kardashian not deterred by bar failure
-
Business18 hours agoMacquarie tips more than 20% upside for this ASX mining stock
-
Noosa News16 hours agoSchools ban e-bikes | Noosa Today
-
Noosa News15 hours agoNRL legend Trevor Gillmeister charged with assaulting police officer at Brisbane pub